Epilepsy drugs row
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.Three-quarters of people with epilepsy suffer side-effects from their drugs but are not receiving new-generation "kinder" treatments because they are too expensive, a survey today claims, writes Celia Hall. The survey of 4,300 epilepsy patients says that most of them are still receiving drugs developed 20 years ago rather than alternatives made available over the past five years.
Terry O'Leary, chief executive of the British Epilepsy Association, said: "If this survey gets patients back to their doctors and specialists asking for their treatment to be reviewed it will have achieved its purpose."
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments